Clear All
765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9073 Brexucabtagene autileucel Tecartus 2000000 Immunotherapy CAR-T CD19 No 2020 Jan 1, 2021 Apr 1, 2021 In Use
J9304 Pemetrexed Pemfexy 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2020 Oct 1, 2020 In Use
Q5111 Pegfilgrastim-cbqv Udenyca 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2019 Jan 1, 2019 In Use
NA Alpelisib Piqray 200mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Zanubrutinib Brukinsa 80mg Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2019 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
C9058 Pegfilgrastim-bmez Ziextenzo 0.5mg Ancillary Therapy immunomodulatorne Granulocyte Colony Stimulating Factor No 2019 Mar 31, 2020 Jul 1, 2020 No Longer Used
NA Pexidartinib Turalio Multiple Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Yes 2019 In Use
NA Entrectinib Rozlytrek 100mg, 200mg Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Yes 2019 In Use
NA Fedratinib Hydrochloride Inrebic 100mg Chemotherapy Enzyme Inhibitor JAK2, FLT3 Yes 2019 In Use
J0896 Luspatercept Reblozyl 0.25mg Ancillary Therapy Erythropoiesis-Stimulating Agent No 2019 Jul 1, 2020 In Use
NA Darolutamide Nubeqa 300mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2019 In Use
Q5120 Pegfilgratim-bmez Ziextenzo 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2019 Jul 1, 2020 In Use
J9394 Fulvestrant (Fresnius) Fulvestrant (Fresnius) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
J9356 Trastuzumab and Hyaluronidase-oysk Herceptin hylecta 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Jul 1, 2019 In Use
J9044 Bortezomib Bortezomib 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2019 Nov 3, 2019 Dec 21, 2022 In Use
Q5119 Rituximab-pvvr Ruxience 10mg Immunotherapy Monoclonal Antibody CD20 No 2019 Jul 1, 2020 In Use
Q5117 Trastuzumab-anns Kanjinti 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Oct 1, 2019 In Use
J1456 Fosaprepitant (Teva) Fosaprepitant (Teva) 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2019 Dec 21, 2022 In Use
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
NA Selinexor Xpovio 20mg, 40mg, 50mg, 60mg Chemotherapy Enzyme Inhibitor XPO1 Yes 2019 In Use
J9309 Polatuzumab Vedotin Polivy 1mg Immunotherapy Drug Antibody Conjugate CD79b No 2019 Jan 1, 2020 In Use
Q5118 Bevacizumab-bvzr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct 1, 2019 In Use
J9177 Enfortumab vedotin-ejfv Padcev 0.25mg Immunotherapy Drug Antibody Conjugate Nectin-4 No 2019 Jul 1, 2020 In Use
J9358 Fam-trastuzumab deruxtecan-nxki Enhertu 1mg Immunotherapy Drug Antibody Conjugate HER2, topoisomerase, tetrapeptide No 2019 Jul 1, 2020 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.